Penn State College of Medicine is advancing its commitment to cutting-edge cancer research and early-phase clinical trials through a new collaboration aimed at accelerating a promising targeted therapy for pediatric brain cancer. Through its leadership of the Beat Childhood Cancer Research Consortium and Four Diamonds in partnership with Targepeutics, the College of Medicine will help advance GB13, a novel immunotherapy for diffuse intrinsic pontine glioma (DIPG), toward clinical trials.
